Pro Medicus, Ltd. · ASX:PME
Pro Medicus — Shareholder Meeting (November 2016)
33 slides from Pro Medicus's shareholder meeting presentation, Nov 22, 2016
Slide 1: Chairman's Address AGM November 2016
1 For personal use only Chairman’s Address AGM November 2016
Slide 2: Welcome and Introduction
PRO MEDICUS LIMITED WELCOME AND INTRODUCTION Ladies and Gentlemen, For personal use only On behalf of my fellow Directors I would like to welcome you to the Annual General Meeting of Pro Medicus Limited and thank you for taking the time to be with us. My name is Peter Kempen and I am the Chairman of
Slide 3: Chairman's Report – Overview
CHAIRMAN’S REPORT Overview The Board has continued to implement its strategic plan during the last financial year which has resulted in the continuing growth of the Company. As I indicated at the last AGM our main focus has been on: For personal use only (a) Scaling up our resources, particularly in
Slide 4: Financial Results
Financial Results The financial results for the 2016 financial year recorded a healthy increase in net profit after tax (2016 $6.368 million: 2015 $3.217 million). This was a very pleasing result considering the level of investment for future growth and was a further For personal use only indication
Slide 5: Closing
Closing In closing, on your behalf, I would like to thank all of our dedicated staff in Australia, North America and Europe for their contribution to the company during what has been another very positive year. I would also like to thank my fellow directors who have also worked tirelessly and dilige
Slide 6: CEO Presentation AGM November 2016
2 For personal use only CEO Presentation AGM November 2016
Slide 7: Pro Medicus
Pro Medicus (ASX:PME) For personal use only Healthcare IT company specialising in Enterprise Medical Imaging and radiology information system software. Leading edge products, growing presence globally. EU Headquarters / R&D Berlin, Germany US Headquarters San Diego, CA Group Headquarters Melbourne O
Slide 8: Product suite
For personal use only PME Ltd Visage 7 * Visage RIS * Pro Medicus.net Product Suite OEM
Slide 9: FY2016 Highlights - Financial Results
FY2016 Highlights - Financial Results For personal use only FY 2 0 15 FY 2 0 16 % Y oY Revenue ($m) 17.49 27.52 57% Profit before tax ($m) 5.11 9.50 86% NPAT - reported ($m) 3.22 6.37 98% NPAT - underlying ($m) 2.15 6.43 199% Cash ($m) 12.94 17.11 32% EPS (cps) 3.20 6.30 97% DPS (cps) 2.00 3.00 50%
Slide 10: FY16 Highlights
FY16 Highlights For personal use only • Increased revenue from US contracts • 4 Key US contract wins in FY 2016 • Contracted revenue over next five years increased by over 65% (PoP) to >$100 million • Visage 7.0 - increasing momentum in US market • Pipeline of Opportunities continued to grow • Austr
Slide 11: July 2016 to Now
July 2016 to Now For personal use only • All implementations progressing on, or ahead of schedule • Network effect from recent sales/reference sites • Growing pipeline • Company tracking well relative to budget • Increase in cash reserves
Slide 12: Visage RIS – New Technology Platform
Visage RIS – New Technology Platform For personal use only • Technology is leading edge • Feedback from customers positive • New clients purchasing both Visage RIS & PACS • Transition of user base nearing completion • Repositioning company as leader in field • Large scale rollouts > 1,500 users on o
Slide 13: Leading Edge Product Set
Leading Edge Product Set – Visage Imaging Still Number 1 in Speed, Functionality, Scalability 9 For personal use only
Slide 14: Sales Time Line – FY 2016
Sales Time Line – FY 2016 For personal use only September 2015 April 2016 July2016 November 2015 April 2016
Slide 15: North American Market
North American Market 11 For personal use only • PACS market estimated at > US$2 billion pa and growing • Paradigm shift to “deconstructed PACS” – best in breed approach • Market fragmented - in process of consolidating • Visage 7.0 – proven, market leading technology • Company ideally positioned to
Slide 16: Massive data explosion
Massive data explosion 12 For personal use only • Higher image density - CT leaps from 64 slices to 256 and now 640 • 3.0T MRI – much larger dataset than 1.5T • Functional Imaging e.g. PET scan often > 1.5 to 2 gigabytes • Digital Breast Tomosynthesis (DBT) files can be over 4 to 6 gigabytes • Prior
Slide 17: "Deconstructed" PACS
“Deconstructed” PACS 13 For personal use only Radiology Urology Gastroenterology Oncology Cardiology Neurology
Slide 18: Electronic Medical Record (EMR)
Electronic Medical Record (EMR) 14 For personal use only • Mandated in US Hospitals by end of 2018 • Consolidates all hospital data – clinical and financial • 90% of EHR is imaging data (by volume) • Need all imaging data in one repository • Driving adoption of VNA • Need for a single viewer for all
Slide 19: Solution - Visage 7.0 Streaming Technology
Solution - Visage 7.0 Streaming Technology 15 For personal use only
Slide 20: Business Model – Operational (Transaction) Based
Business Model – Operational (Transaction) Based 16 For personal use only • Alternative to traditional upfront licence model • Favoured in recent US contracts • Based on guaranteed minimums [insert chart comparing • Upside as client examination volumes grow transaction with • Annuity style revenue s
Slide 21: Margin Expansion
Margin Expansion 17 For personal use only • Highly scalable offering • No Capex (HW) – SW only model • Training & Installation – charged as professional services • Relatively fixed cost base • Margin growth as footprint increases
Slide 22: PME - Repositioned in Market
PME - Repositioned in Market 18 For personal use only • Unique, leading edge technology • Rapidly expanding US footprint • Growing number of large/prestigious clients. • Products have “natural advantage” in their markets • Looking to further leverage our world-class R&D/Research capability
Slide 23: Proven Results
Proven Results 19 For personal use only • Growing reputation for successful implementations • Proven IT and infrastructure savings • Industry leading efficiency gains • Greater clinical accuracy • Delivers superior value proposition
Slide 24: Pipeline
Pipeline 20 For personal use only • Multiple opportunities at various stages of cycle • New opportunities since recent wins [insert chart • No opportunities lost since recent announcements comparing transaction with • Opportunities in both private and large enterprise capital model] markets • Networ
Slide 25: Marketing - North America
Marketing - North America For personal use only http://www.medcpu.com/wp- http://www.rsna.org/uploadedImages/RSNA/Co ntent/Annual_Meeting/2015/Top_Banner.png content/uploads/2015/01/RSNA-873x457.jpg
Slide 26: Marketing - North America
Marketing - North America For personal use only • Building on the success of RSNA 2015
Slide 27: Growth Strategy
Growth Strategy 23 For personal use only • Transaction growth (above minimums) from existing clients • Expand current footprint via new deals • Margin expansion with future contracts • Continue to build out pipeline • Extend to other markets • Leverage R&D capability to introduce new products
Slide 28: New products - Enterprise Imaging
New products - Enterprise Imaging 24 For personal use only • One viewer for all images in the medical record (EMR) • Radiology/Cardiology (DICOM format) • Non radiology - reflected light - hi res photos & video • Visage ideally suited – any image streamed anywhere. • Significantly increases Visage v
Slide 29: Visage Imaging – One Viewer All Images
VISAGE TMAGING’ @ ONEVIEWER ALLIMAGES Diagnostic - Clinical - EHR - 3D + Cardiology - Breast Imaging + Specialties - Telerad —_— At Home/Remote - Non-DICOM - Visible Light - Multimedia - HD Video + Audio - QA .
Slide 30: One Viewer - Enterprise Imaging
One Viewer - Enterprise Imaging 26 For personal use only
Slide 31: Global Management Structure
Global Management Structure 27 For personal use only Malte Westerhoff – Chief Technology Officer Sean Lambright - Head of Sales Brad Levin – Head of Marketing Teresa Gschwind – Head of Services
Slide 32: Summary
Summary 28 For personal use only • Unique market position • Leading edge technology • Proven implementation & support capability • Delivers measureable financial benefits • Meaningful improvement in clinical outcomes • Unparalleled value proposition • Looking to further leverage R&D/Research capabil
Slide 33: Thank you
29 For personal use only Thank you AGM November 2016